A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

BACKGROUND: This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms C, D) in combination with the MEK inhibitor PD-0325901 (arm A, D) or irinotecan (arm B, C) in patients with advanced solid tumors. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainberg, Zev A., Alsina, Maria, Soares, Heloisa P., Braña, Irene, Britten, Carolyn D., Del Conte, Gianluca, Ezeh, Patrick, Houk, Brett, Kern, Kenneth A., Leong, Stephen, Pathan, Nuzhat, Pierce, Kristen J., Siu, Lillian L., Vermette, Jennifer, Tabernero, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700209/
https://www.ncbi.nlm.nih.gov/pubmed/29067643
http://dx.doi.org/10.1007/s11523-017-0530-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700209/
https://www.ncbi.nlm.nih.gov/pubmed/29067643
http://dx.doi.org/10.1007/s11523-017-0530-5

Ejemplares similares